Artificial intelligence to solve healthcare's biggest challenge: neurodegenerative disease

Neurodegenerative diseases represent a growing global crisis. The current estimated cost to society is over $650 billion worldwide, and projected to reach over $1 trillion per year by 2020. Currently, no treatments prevent or stop the progression of the major neurodegenerative diseases.

In the past, most neuroscientists did not have the tools to disentangle the complex genetics of these diseases. Accelerating advances in human genomics, combined with recent insights into neurobiology, have created an unprecedented opportunity for the discovery of breakthrough treatments in the central nervous system (CNS). Our platform is specifically designed for neurological diseases, and can analyze thousands of datasets to identify new targets, predict effective drugs, and stratify patient subpopulations. Verge's genomic network approach offers a breakthrough opportunity to identify drugs that dramatically improve patient outcomes and fundamentally bend the cost curve of pharmaceutical development.

The result: fewer failed drugs, cures for patients within their lifetimes.